Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Subjects
- Location of subjects
- Netherlands
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- control (no treatment) - week 1
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- infants who received short-term or long-term antibiotic treatment - week 1
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- infants born between 32-42 weeks of gestation and admitted to the hospital (level III neonatal intensive care or level II neonatal ward) who received short-term antibiotics (<3 days) or longterm antibiotics (>5 days)
- Group 0 sample size Number of subjects in the control (unexposed) group
- 28
- Group 1 sample size Number of subjects in the case (exposed) group
- 35
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Kruskall-Wallis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Text
Description: Differences in gut microbiota composition between infants receiving no, short or long antibiotic treatment
Abundance in Group 1: increased abundance in infants who received short-term or long-term antibiotic treatment - week 1
NCBI | Quality Control | Links |
---|---|---|
Lactobacillus |
Revision editor(s): WikiWorks
Signature 2
Source: Text
Description: Differences in gut microbiota composition between infants receiving no, short or long antibiotic treatment
Abundance in Group 1: decreased abundance in infants who received short-term or long-term antibiotic treatment - week 1
NCBI | Quality Control | Links |
---|---|---|
Escherichia | ||
Streptococcus |
Revision editor(s): WikiWorks
Experiment 2
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- control(no treatment) - week 2
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- infants received long-term(>5days) antibiotic treatment - week 2
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- infants born between 32-42 weeks of gestation and admitted to the hospital (level III neonatal intensive care or level II neonatal ward) who received >5 days antibiotics, week 2 timepoint
- Group 1 sample size Number of subjects in the case (exposed) group
- 13
Lab analysis
Statistical Analysis
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Text
Description: Differences in gut microbiota composition between infants receiving no, short or long antibiotic treatment
Abundance in Group 1: increased abundance in infants received long-term(>5days) antibiotic treatment - week 2
NCBI | Quality Control | Links |
---|---|---|
Enterococcus |
Revision editor(s): WikiWorks, Claregrieve1
Experiment 3
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- infants received short-term (<3days) antibiotic treatment - week 1
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- infants received long-term (>5days) antibiotic treatment - week 1
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- infants born between 32-42 weeks of gestation and admitted to the hospital (level III neonatal intensive care or level II neonatal ward) who received longterm (>5 days) antibiotics, first post-natal week timepoint
- Group 0 sample size Number of subjects in the control (unexposed) group
- 22
Lab analysis
Statistical Analysis
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Text
Description: Differential microbial abundance between infants who received short-term and long-term antibiotics
Abundance in Group 1: decreased abundance in infants received long-term (>5days) antibiotic treatment - week 1
NCBI | Quality Control | Links |
---|---|---|
Clostridium sp. |
Revision editor(s): Claregrieve1
Signature 2
Source: Text
Description: Differential microbial abundance between infants who received short-term and long-term antibiotics
Abundance in Group 1: increased abundance in infants received long-term (>5days) antibiotic treatment - week 1
NCBI | Quality Control | Links |
---|---|---|
Veillonella |
Revision editor(s): Claregrieve1